Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Stroke
Interventions: Transcranial direct current stimulation (tDCS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma, Stage IVB Thymoma
Interventions: saracatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Stanford, California • Indianapolis, Indiana

Conditions: Breast Cancer
Interventions: Curcumin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Urothelial Carcinoma
Interventions: retifanlimab, epacadostat, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
Interventions: Erdafitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Monitoring for Low Minute Ventilation Post Surgery
Interventions: Non-Invasive Respiratory Volume Monitor; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: Sacituzumab Govitecan, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts

Conditions: Diabetic Foot Ulcer
Interventions: SnapshotNIR, Kent Imaging; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Interventions: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 36
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: 89Zr-DFO-girentuximab; Diagnostic Test
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years to 99 Years
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Pharmacokinetics
Interventions: BCG in Combination with N-803, N-803 alone; Biological · Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Omaha, Nebraska + 3 more

Conditions: Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions: AirGo Respiratory Monitor; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative
Interventions: liposomal bupivicaine; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions: Agent Affecting Integumentary System, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Postoperative Pain
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Functional Movement Disorder
Interventions: MagStim, Sham Comparator; Device · Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions: Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC); Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Intracranial Pressure
Interventions: CPMX3 measurement; Device
Lead sponsor: Compremium AG; Industry
Eligibility: 8 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Tracheobronchomalacia
Interventions: nPEP (non-invasive positive expiratory pressure) mask; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Aphasia, Stroke, Acute
Interventions: Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Transplant
Interventions: Prospera; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more

Conditions: Jaw Fractures, Jaw; Fracture, Upper Jaw, Mandibular Fractures, Maxilla Fracture, Jaw Fixation
Interventions: dental occlusion ties maxillo-mandibular fixation; Device
Lead sponsor: Altru Health System; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Search by objective public record fields.

Home-based Non-invasive Brain Stimulation and Hand Tracking Rehabilitation for People With Chronic Stroke

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Evaluation of Non-Invasive Respiratory Volume Monitor

Sacituzumab Govitecan In TNBC

Non-Invasive Testing to Evaluate Wound Healing in Diabetes

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

89Zr-DFO-girentuximab Expanded Access Program (EAP)

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders

Microvascular and Fibrosis Imaging Study

Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Normal Volunteers

Validation of Non-Invasive Intracranial Pressure Estimation Using CPMX3 in the Periorbital Vein: A Feasibility Study in Pediatric Patients

PEEP Mask for Tracheobronchomalacia-Induced Cough

tDCS to Treat Subacute Aphasia

Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation

Minimally Invasive Dental Occlusion Ties